Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.49 |
| ▸ | FEN1 | P39748 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19462318 | 0.94 | PDE4B (0.52) | SCN9ACHEK2PDE4BALOX5APFEN1 | |
| SCHEMBL19462274 | 0.94 | PDE4B (0.52) | SCN9ACHEK2PDE4BALOX5APFEN1 | |
| SCHEMBL13419707 | 0.89 | SCN9A (0.62) | SCN9ACHEK2PDE4BALOX5APFEN1 | |
| SCHEMBL16980718 | 0.89 | SCN9A (0.62) | SCN9ACHEK2ALOX5APFEN1BACE1 | |
| SCHEMBL27157955 | 0.86 | SCN9A (0.55) | SCN9ACHEK2PDE4BALOX5APFEN1 | |
| SCHEMBL4031568 | 0.84 | SCN9A (0.51) | SCN9ACHEK2PDE4BALOX5APFEN1 | |
| SCHEMBL21280426 | 0.84 | PDE4B (0.46) | SCN9APDE4BALOX5APFEN1NR1H2 | |
| SCHEMBL447381 | 0.82 | RBP4 (0.53) | SCN9ACHEK2PDE4BALOX5APFEN1 | |
| SCHEMBL5068253 | 0.81 | SCN9A (0.54) | SCN9ACHEK2PDE4BALOX5APFEN1 | |
| SCHEMBL5163390 | 0.81 | SCN9A (0.54) | SCN9ACHEK2PDE4BALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
| EP-1497265-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | SCN9A 125/4885CHEK2 2778/4885PDE4B 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.